Screener
Regeneron Pharmaceuticals REGN Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Marketable securities | 9,828.3 | 10,260.6 |
| Property, plant, and equipment, net | 5,458.9 | 5,120.4 |
| Intangible assets, net | 1,309.8 | 1,257.4 |
| Deferred tax assets | 4,381.4 | 4,077.2 |
| Other noncurrent assets | 2,306.2 | 1,821.2 |
| Total assets | $41,730.6 | $40,558.7 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's deferred tax assets?
- Regeneron Pharmaceuticals (REGN) reported deferred tax assets of $4.38B in Q2 2026.
- How has Regeneron Pharmaceuticals's deferred tax assets changed year-over-year?
- Regeneron Pharmaceuticals's deferred tax assets increased by 3140.7% year-over-year, from $135.2M to $4.38B.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred tax assets?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's deferred tax assets has grown at a 136.9% compound annual growth rate (CAGR), from $147.1M to $4.63B.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Regeneron Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude